Common Side Effects of GLP-1 Medications in Frankfort, IN

GLP-1 medication side effects are usually gastrointestinal and are often most noticeable when treatment begins or the dose increases.

Medications in this group include:

• Wegovy, or semaglutide
• Ozempic, or semaglutide
• Zepbound, or tirzepatide
• Mounjaro, or tirzepatide
• Saxenda, or liraglutide

Tirzepatide is more accurately described as a dual GIP and GLP-1 receptor agonist, but it is commonly discussed alongside GLP-1 medications because it shares GLP-1 receptor activity and many of the same gastrointestinal effects.

The most common side effects across these medications include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal discomfort or pain
• Indigestion
• Bloating
• Belching
• Acid reflux or heartburn

Other recognized effects can include:

• Reduced appetite
• Fatigue
• Dizziness
• Headache
• Injection-site reactions
• Hair loss
• Altered skin sensation, especially with higher-dose semaglutide

Mild symptoms can often be managed with nutrition, hydration and medication-titration strategies.

Severe or persistent symptoms should not be treated as something patients simply have to tolerate.

A physician-guided medical weight-loss program can help distinguish expected side effects from symptoms that require medical evaluation.

To discuss GLP-1 medication side effects in Frankfort, IN, call (765) 259-0545 or contact Charles Turner MD online.

Why Do GLP-1 Medications Cause Side Effects?

GLP-1 and GLP-1-based medications affect several systems at the same time.

They can:

• Reduce appetite
• Increase satiety
• Slow gastric emptying
• Change insulin and glucagon signaling
• Reduce calorie intake

These same mechanisms that help with glucose control and weight reduction can also cause gastrointestinal symptoms.

For example, slower gastric emptying can contribute to:

• Fullness
• Nausea
• Belching
• Reflux
• Bloating

Are Side Effects the Same With Every GLP-1 Medication?

No.

The general pattern overlaps, but individual drugs differ in:

• Molecular structure
• Receptor activity
• Dose
• Route
• Duration of action
• Clinical indication

Side-effect percentages also come from different trials and different patient populations.

A patient should not assume that a medication with a lower percentage in one product label will automatically be easier to tolerate than another product studied in a different population.

Quick Comparison of Common GLP-1 Side Effects

Medication	Commonly Reported Effects
Wegovy	Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, reflux, gas, hair loss and dysesthesia
Ozempic	Nausea, vomiting, diarrhea, abdominal pain and constipation; less common recognized effects include indigestion, belching, reflux, fatigue, dizziness and dysesthesia
Zepbound	Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss and reflux
Mounjaro	Nausea, diarrhea, reduced appetite, vomiting, constipation, indigestion and abdominal pain
Saxenda	Nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, hypoglycemia in selected patients, indigestion, fatigue, dizziness and abdominal pain

This table summarizes current product-label patterns. It is not a head-to-head safety ranking.

How Common Is Nausea?

Nausea is one of the most common effects of GLP-1-based treatment.

In current adult obesity-treatment labeling:

• Wegovy 2.4 mg reported nausea in approximately 44% of treated adults
• Zepbound reported nausea in approximately 25% to 29% of adults across 5 mg, 10 mg and 15 mg weight-management doses
• Saxenda reported nausea in approximately 39% of treated adults

In diabetes-treatment labeling:

• Ozempic reported nausea in approximately 16% to 20% of adults at 0.5 mg and 1 mg
• Mounjaro reported nausea in approximately 12% to 18% of adults across 5 mg, 10 mg and 15 mg

These percentages come from different trials and should not be directly compared as though the products were randomized against one another.

Why Is Nausea Often Worse During Dose Escalation?

The gastrointestinal tract and appetite-regulation system are adapting to a stronger medication effect.

Current semaglutide and tirzepatide labels specifically note that nausea, vomiting and diarrhea are most common during dose escalation and often decrease with time.

This is one reason approved regimens use gradual titration rather than starting at the full maintenance dose.

What Can Help Mild GLP-1 Nausea?

Practical strategies can include:

• Eating smaller meals
• Eating slowly
• Stopping before feeling overly full
• Avoiding very large high-fat meals
• Maintaining adequate hydration
• Choosing simpler foods during symptom flares
• Avoiding lying down immediately after a large meal

GLP-1 weight loss coaching can help patients identify symptom patterns and adjust meal structure.

When Is Nausea More Than a Common Side Effect?

Medical review is important when nausea is accompanied by:

• Persistent vomiting
• Inability to keep fluids down
• Severe abdominal pain
• Fainting
• Signs of dehydration
• Marked weakness
• Jaundice
• Severe abdominal distention

These symptoms may signal something more serious than routine medication-related nausea.

Vomiting With GLP-1 Medications

Vomiting is less common than nausea but remains one of the most recognized gastrointestinal effects.

Current labels report approximately:

• 24% with Wegovy 2.4 mg in adult obesity trials
• 8% to 13% across Zepbound weight-management doses
• 16% with Saxenda in adult obesity trials
• 5% to 9% with Ozempic 0.5 mg to 1 mg in diabetes trials
• 5% to 9% across Mounjaro 5 mg to 15 mg in diabetes trials

Repeated vomiting can become medically important because it can lead to dehydration, electrolyte abnormalities and kidney injury.

When Should Vomiting Be Reported?

Contact the medical team when vomiting:

• Persists
• Prevents adequate fluid intake
• Occurs with severe abdominal pain
• Causes dizziness or fainting
• Produces signs of dehydration
• Occurs repeatedly after a dose increase

A patient should not continue escalating medication when significant vomiting has not been discussed with the prescriber.

Diarrhea With GLP-1 Medications

Diarrhea is another common effect.

Current labels report approximately:

• 30% with Wegovy 2.4 mg
• 19% to 23% across Zepbound weight-management doses
• 21% with Saxenda
• About 9% with Ozempic 0.5 mg to 1 mg
• 12% to 17% across Mounjaro doses

Most episodes are mild to moderate, but persistent diarrhea can cause dehydration.

What Can Help Mild Diarrhea?

Depending on the patient, practical steps may include:

• Maintaining fluid intake
• Using smaller meals
• Avoiding foods that repeatedly worsen symptoms
• Reducing very high-fat meals
• Tracking whether symptoms are linked to dose escalation

Patients should be cautious about aggressively treating persistent diarrhea with over-the-counter medication without understanding the cause.

Constipation With GLP-1 Medications

Constipation can result from a combination of:

• Reduced food intake
• Reduced fluid intake
• Slower gastrointestinal transit
• Lower fiber intake
• Reduced physical activity

Current adult weight-management labels report constipation in approximately:

• 24% with Wegovy 2.4 mg
• 11% to 17% across Zepbound doses
• 19% with Saxenda

Constipation is generally less frequent in the diabetes-label trials for Ozempic and Mounjaro, although it still occurs.

What Can Help Mild Constipation?

Useful first steps can include:

• Consistent hydration
• Gradually increasing fiber when tolerated
• Walking and physical activity
• Maintaining regular food intake
• Including vegetables, fruit, beans, lentils and whole grains when tolerated

Increasing fiber very quickly while drinking too little fluid can make symptoms worse.

When Is Constipation Concerning?

Prompt medical evaluation is important when constipation is accompanied by:

• Severe abdominal distention
• Persistent vomiting
• Severe or worsening abdominal pain
• Inability to pass stool
• Inability to pass gas

Current postmarketing labeling for semaglutide and tirzepatide includes reports of:

• Ileus
• Intestinal obstruction
• Severe constipation including fecal impaction

These reports do not tell us how often the events occur or prove that the medication caused every case, but the symptoms should not be ignored.

Abdominal Pain and Cramping

Mild abdominal discomfort can occur with GLP-1 medications.

Potential reasons include:

• Slower gastric emptying
• Gas
• Constipation
• Diarrhea
• Eating past fullness

Persistent, severe or localized pain requires a different level of attention.

When Abdominal Pain May Signal Pancreatitis

Pancreatitis is uncommon but medically important.

Symptoms can include:

• Severe persistent upper-abdominal pain
• Pain that may radiate to the back
• Nausea
• Vomiting

Patients with symptoms concerning for pancreatitis require prompt medical evaluation.

Do not assume severe abdominal pain is simply a routine GLP-1 side effect.

Gallstones and Gallbladder Inflammation

GLP-1-based treatment and substantial weight loss can both be associated with gallbladder problems.

Potential symptoms include:

• Persistent pain in the upper right abdomen
• Fever
• Yellowing of the skin or eyes
• Clay-colored stools
• Nausea or vomiting

Gallbladder symptoms warrant medical evaluation.

Why Rapid Weight Loss Can Affect the Gallbladder

Rapid or substantial weight reduction can change bile composition and gallbladder emptying.

This can increase gallstone risk independent of the medication itself.

The possibility of gallbladder disease therefore reflects both:

• Medication-related physiology
• The biological effects of rapid weight reduction

Indigestion and Dyspepsia

Indigestion can include:

• Upper-abdominal discomfort
• Early fullness
• Post-meal heaviness
• Burning or discomfort

Dyspepsia is recognized in the current labeling of multiple GLP-1-based medications.

Smaller meals and avoiding very heavy meals can help some patients.

Acid Reflux and Heartburn

Reflux can become more noticeable because delayed stomach emptying can increase fullness after eating.

Strategies may include:

• Smaller meals
• Avoiding very late large meals
• Avoiding lying down soon after eating
• Reducing foods that repeatedly trigger reflux
• Reducing very large high-fat meals

Persistent reflux or difficulty swallowing should be medically evaluated.

Belching and Gas

Belching, or eructation, and flatulence are recognized effects in several product labels.

They may reflect:

• Delayed gastric emptying
• Altered meal size
• Changes in food choice
• Constipation

Eating more slowly and reducing very large meals can help some patients.

Bloating and Abdominal Distention

Mild bloating can occur during dose escalation.

Patients should distinguish routine bloating from severe progressive distention.

Severe distention with vomiting or inability to pass gas or stool requires prompt medical evaluation.

Reduced Appetite

Reduced appetite is an expected pharmacologic effect, especially with tirzepatide.

However, appetite can become too low for some patients.

Excessive appetite suppression can contribute to:

• Inadequate protein intake
• Dehydration
• Micronutrient deficiencies
• Weakness
• Loss of lean mass

Nutritional counseling can help patients maintain adequate intake even when hunger is reduced.

When Reduced Appetite Becomes a Problem

A clinician should review treatment when a patient is:

• Regularly eating very little
• Unable to meet fluid needs
• Losing strength
• Experiencing persistent dizziness
• Losing weight much faster than intended
• Unable to tolerate normal food intake

The goal of obesity treatment is not to make eating impossible.

Fatigue

Fatigue is reported with several GLP-1-based medications.

Possible contributors include:

• Lower calorie intake
• Dehydration
• Rapid weight loss
• Poor sleep
• Low blood pressure
• Hypoglycemia in selected patients
• Loss of conditioning

Persistent fatigue should not automatically be blamed on the medication.

Other medical causes may need evaluation.

Dizziness

Dizziness can occur during treatment.

Possible causes include:

• Dehydration
• Lower blood pressure
• Hypoglycemia
• Reduced calorie intake
• Other medications

Repeated dizziness or fainting requires medical review.

Low Blood Pressure

Weight loss can lower blood pressure over time.

Zepbound labeling also reports hypotension more often than placebo, especially in patients taking blood-pressure medication.

A clinician may need to reassess antihypertensive therapy when a patient develops:

• Light-headedness
• Orthostatic dizziness
• Fainting
• Unusually low home blood-pressure readings

Headache

Headache is recognized with semaglutide and liraglutide products.

Potential contributors include:

• Dehydration
• Reduced food intake
• Caffeine changes
• Hypoglycemia
• Sleep disruption

Severe, unusual or persistent headaches should be evaluated according to the complete clinical picture.

Injection-Site Reactions

Injection-site reactions can include:

• Redness
• Itching
• Bruising
• Minor pain
• Rash

They are particularly recognized with tirzepatide and liraglutide products.

Rotating injection sites can help reduce repeated irritation in the same area.

Severe swelling, widespread hives or breathing difficulty is not a routine injection-site reaction and requires urgent medical attention.

Hair Loss

Hair loss is listed in current Wegovy and Zepbound labeling and has also been reported postmarketing with semaglutide.

Hair shedding during substantial weight loss can reflect several factors:

• Rapid weight reduction
• Lower calorie intake
• Low protein intake
• Iron deficiency
• Other micronutrient deficiencies
• Physiologic stress from major body-weight change

Zepbound's current label notes that hair-loss reactions were associated with weight reduction.

Does Hair Loss Mean the Medication Is Damaging Hair Follicles?

Not necessarily.

Rapid weight loss from many causes can trigger temporary diffuse hair shedding.

Persistent hair loss may justify evaluation of:

• Protein intake
• Iron status
• Thyroid function
• Other nutritional factors
• Other medications

Selected patients may benefit from blood testing when clinically indicated.

Dysesthesia and Altered Skin Sensation

Dysesthesia means an abnormal or uncomfortable skin sensation.

Patients may describe:

• Tingling
• Burning
• Heightened skin sensitivity
• Painful skin
• Altered sensation

Dysesthesia is now a recognized semaglutide adverse effect.

It is especially notable with higher-dose Wegovy.

How Common Is Dysesthesia With Wegovy HD?

In current Wegovy labeling, dysesthesia occurred in approximately:

• 22% of patients receiving Wegovy 7.2 mg injection
• 6% receiving Wegovy 2.4 mg injection
• 0.3% receiving placebo

The label also reports dysesthesia with Wegovy tablets, although less frequently than with the 7.2 mg injection.

Patients should report persistent or severe altered skin sensation.

What Is Wegovy HD?

Wegovy HD is the higher 7.2 mg once-weekly semaglutide injection approved for selected adults who tolerate 2.4 mg and need additional weight reduction.

Patients can review semaglutide injections and Wegovy therapy for the full current dosing framework.

Can GLP-1 Medications Cause Muscle Loss?

Weight loss from GLP-1-based treatment includes mostly fat mass but can also include lean tissue.

This is not usually classified as a simple medication “side effect” in the same way as nausea or vomiting.

It is a body-composition consequence of substantial weight reduction that deserves attention.

How Can Patients Reduce Lean-Mass Loss?

Strategies can include:

• Adequate protein intake
• Resistance training
• Avoiding extreme calorie restriction
• Monitoring strength
• Correcting nutritional deficiencies

Patients with low baseline muscle mass may need evaluation for sarcopenia.

Body composition analysis and body composition tracking can help distinguish fat loss from lean-mass change.

Can GLP-1 Medications Cause Dehydration?

The medications do not usually cause dehydration directly.

Dehydration can develop because of:

• Vomiting
• Diarrhea
• Very low fluid intake
• Reduced appetite and thirst

Severe dehydration can lead to:

• Dizziness
• Low blood pressure
• Electrolyte abnormalities
• Acute kidney injury

GLP-1 Medications and Acute Kidney Injury

Acute kidney injury has been reported with semaglutide, liraglutide and tirzepatide products, often in the setting of gastrointestinal fluid loss.

Patients with existing kidney disease may have less reserve if dehydration develops.

Contact the medical team when:

• Vomiting or diarrhea does not stop
• Fluid intake is inadequate
• Urine output decreases markedly
• There is fainting or severe weakness

Do GLP-1 Medications Cause Gastroparesis?

GLP-1-based medications slow gastric emptying.

This does not mean every patient develops clinical gastroparesis.

However, severe persistent symptoms may warrant evaluation for delayed gastric emptying.

Symptoms can include:

• Persistent nausea
• Repeated vomiting
• Severe prolonged fullness
• Difficulty finishing small meals
• Upper-abdominal discomfort

Current product labels generally do not recommend these medications in patients with severe gastroparesis.

Can GLP-1 Medications Cause Intestinal Obstruction?

Postmarketing reports with semaglutide and tirzepatide include:

• Ileus
• Intestinal obstruction
• Severe constipation with fecal impaction

Because postmarketing reports are voluntary, they cannot reliably establish frequency or prove causation in every case.

Symptoms such as severe distention, persistent vomiting or inability to pass stool or gas require urgent assessment.

GLP-1 Medications and Hypoglycemia

GLP-1 medications generally have a lower intrinsic risk of severe hypoglycemia than insulin or sulfonylureas because insulin secretion is glucose-dependent.

Risk increases when GLP-1-based therapy is combined with:

• Insulin
• Sulfonylureas
• Other insulin-secretagogue medications

Symptoms of low blood sugar can include:

• Shaking
• Sweating
• Hunger
• Dizziness
• Confusion
• Weakness
• Rapid heartbeat

Patients with diabetes should have a clinician-directed hypoglycemia plan.

Diabetic Retinopathy and Rapid Glucose Improvement

Patients with type 2 diabetes and established diabetic retinopathy may need additional eye monitoring during potent glucose-lowering treatment.

Rapid improvement in glucose can temporarily worsen diabetic retinopathy in some patients.

New or changing vision symptoms should be reported promptly.

This issue is especially relevant when the medication produces a rapid drop in hemoglobin A1c.

Do GLP-1 Medications Affect Heart Rate?

Some products can modestly increase resting heart rate.

For example:

• Semaglutide labels report small mean heart-rate increases
• Saxenda labeling reports an average resting-heart-rate increase of approximately 2 to 3 beats per minute

Patients should report persistent palpitations or sustained racing heartbeat at rest.

Serious Allergic Reactions

Anaphylaxis and angioedema have been reported with semaglutide, tirzepatide and liraglutide.

Seek immediate medical care for symptoms such as:

• Swelling of the face, lips, tongue or throat
• Difficulty breathing
• Difficulty swallowing
• Fainting
• Severe widespread rash

This is different from a mild local injection-site reaction.

GLP-1 Medications and Anesthesia

GLP-1-based medications delay gastric emptying.

Postmarketing reports describe pulmonary aspiration in patients undergoing general anesthesia or deep sedation.

Patients should tell all relevant clinicians they use a GLP-1-based medication before:

• Surgery
• Endoscopy
• Procedures requiring general anesthesia
• Procedures requiring deep sedation

The anesthesia or procedural team should determine the medication and fasting plan.

Do Not Hide GLP-1 Use Before a Procedure

A patient may feel tempted to omit medication history because of concern that a procedure could be delayed.

That can increase risk.

The procedural team needs accurate information about:

• The medication
• The dose
• When it was last taken
• Current gastrointestinal symptoms

Thyroid C-Cell Tumor Warnings

Semaglutide, liraglutide and tirzepatide products carry boxed warnings concerning thyroid C-cell tumors observed in rodents.

It is unknown whether these medications cause medullary thyroid carcinoma in humans.

They are contraindicated in patients with:

• A personal history of medullary thyroid carcinoma
• A family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2

Patients should discuss relevant personal and family history before treatment.

What About Suicidal Thoughts and GLP-1 Medications?

Earlier labeling for Wegovy, Zepbound and Saxenda included warnings concerning suicidal behavior and ideation.

In January 2026, FDA announced the results of a comprehensive review and stated that available evidence did not identify an increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonist medications.

FDA requested removal of the prior warning from:

• Wegovy
• Zepbound
• Saxenda

The current labels reflect that update.

New depression, suicidal thoughts or major mood changes still deserve prompt mental-health evaluation regardless of medication use.

Pregnancy and GLP-1 Weight-Loss Medications

Intentional medication-assisted weight loss is not appropriate during pregnancy.

Pregnancy recommendations differ somewhat by product.

Patients who are:

• Pregnant
• Trying to conceive
• Planning pregnancy

should review medication timing with the prescribing clinician.

Semaglutide has a long washout period, and current labels recommend stopping selected semaglutide therapy in advance of planned pregnancy.

Tirzepatide and Oral Birth-Control Pills

Tirzepatide can reduce exposure to oral hormonal contraceptives because it delays gastric emptying.

Current tirzepatide labeling advises patients using oral hormonal contraception to:

• Switch to a non-oral method, or
• Add a barrier contraceptive method

for four weeks after starting treatment and for four weeks after each dose increase.

This is an important medication interaction rather than a typical side effect.

Do Side Effects Mean the Medication Is Too Strong?

Not always.

Mild nausea, constipation or diarrhea can occur even at an appropriate dose.

However, persistent symptoms may indicate that:

• The dose escalation is too fast for the individual
• The current dose is not well tolerated
• Nutrition or hydration needs adjustment
• A separate medical condition is present

A prescriber should decide whether the medication schedule needs to change.

Can the Dose Be Lowered Because of Side Effects?

Sometimes.

Appropriate adjustments depend on:

• The specific medication
• The current dose
• The indication
• The severity of symptoms
• How long the patient has been at the dose

Patients should not create their own dosing intervals or partial-dose protocols unless specifically instructed by the prescribing clinician.

Can Dose Escalation Be Delayed?

Several approved GLP-1 weight-management regimens allow a clinician to delay escalation when tolerability is poor.

That is one reason patients should report significant symptoms before the next scheduled dose increase.

Reaching the maximum dose as quickly as possible is not the treatment goal.

Why Medication Titration Matters

Clinical trials consistently show that gastrointestinal events cluster around dose escalation.

Slow titration provides time for:

• Gastrointestinal adaptation
• Hydration planning
• Meal-size adjustment
• Symptom monitoring

Faster titration can increase side-effect burden without guaranteeing better long-term results.

What Can GLP-1 Weight Loss Coaching Help With?

GLP-1 weight loss coaching can support patients with:

• Smaller meal planning
• Protein intake
• Hydration
• Constipation prevention
• Resistance training
• Side-effect tracking
• Weight-loss plateaus
• Long-term maintenance

Coaching does not replace medical evaluation for severe symptoms.

How Can Nutrition Affect Side Effects?

Food volume and composition can strongly influence gastrointestinal tolerance.

Some patients notice worse symptoms after:

• Very large meals
• Very high-fat meals
• Eating quickly
• Eating past fullness
• Heavy alcohol intake

The ideal eating pattern should be individualized.

Can Eating Too Little Cause Side Effects?

Yes.

Very low food intake can contribute to:

• Fatigue
• Dizziness
• Weakness
• Headache
• Constipation
• Muscle loss

The medication should support appropriate calorie reduction, not chronic undernutrition.

Why Protein Matters When Appetite Is Low

Protein helps support:

• Muscle
• Strength
• Recovery
• Satiety

Patients who lose appetite may need to prioritize protein earlier in meals.

Protein needs should be individualized rather than based on one universal number.

Can Exercise Make Side Effects Worse?

Exercise itself is usually beneficial, but intense exercise can feel harder when a patient is:

• Dehydrated
• Undereating
• Nauseated
• Experiencing low blood pressure
• At risk of hypoglycemia

Exercise intensity may need temporary adjustment during significant symptom flares.

Exercise and Muscle Preservation

Resistance training can help preserve strength and lean mass during weight loss.

Personal training for weight loss may be useful for patients who need a structured plan.

What About Side Effects During a Weight-Loss Plateau?

Side effects and weight loss do not always move together.

A patient may reach a weight-loss plateau while gastrointestinal symptoms continue.

That is an important reason not to increase the dose automatically.

A clinician should review:

• Current response
• Tolerability
• Nutrition
• Physical activity
• Body composition

Wegovy Side Effects

Current Wegovy labeling lists common adult adverse reactions including:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Headache
• Fatigue
• Indigestion
• Dizziness
• Bloating
• Belching
• Gas
• Reflux
• Hair loss
• Dysesthesia

Patients can review Wegovy therapy for current indications and dosing.

Wegovy HD 7.2 mg Side Effects

The higher 7.2 mg Wegovy dose produces greater semaglutide exposure.

The most notable newer safety distinction is dysesthesia.

Current labeling reports dysesthesia in:

• 22% with Wegovy 7.2 mg
• 6% with Wegovy 2.4 mg
• 0.3% with placebo

Gastrointestinal side effects also remain important at the higher dose.

Ozempic Side Effects

The most common current Ozempic adverse reactions are:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Constipation

Postmarketing labeling also includes:

• Ileus
• Intestinal obstruction
• Severe constipation including fecal impaction
• Dysesthesia
• Alopecia

Patients can review Ozempic therapy .

Zepbound Side Effects

Current Zepbound labeling lists common effects including:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Indigestion
• Injection-site reactions
• Fatigue
• Hypersensitivity reactions
• Belching
• Hair loss
• Reflux

Patients can review Zepbound therapy .

Mounjaro Side Effects

Current Mounjaro labeling lists the most common adult effects as:

• Nausea
• Diarrhea
• Reduced appetite
• Vomiting
• Constipation
• Indigestion
• Abdominal pain

Patients can review Mounjaro therapy .

Saxenda Side Effects

Current Saxenda labeling identifies common effects including:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Injection-site reactions
• Headache
• Hypoglycemia in selected patients
• Indigestion
• Fatigue
• Dizziness
• Abdominal pain

Patients can review Saxenda therapy .

Which GLP-1 Medication Has the Fewest Side Effects?

There is no reliable answer that applies to every patient.

Side-effect rates cannot be ranked simply by comparing percentages across separate product labels.

Tolerability depends on:

• Drug
• Dose
• Rate of escalation
• Medical history
• Food intake
• Hydration
• Other medications
• Individual biological response

Some patients tolerate one incretin medication much better than another.

Does a Higher Dose Always Cause More Side Effects?

Not every side effect increases in a perfectly linear way with dose.

However, higher drug exposure can increase certain adverse effects.

Clear examples include:

• Higher dysesthesia rates with Wegovy 7.2 mg than 2.4 mg
• Increasing nausea rates across Mounjaro dose groups in adult diabetes trials

The best dose is the one that provides appropriate clinical benefit with acceptable tolerability.

Can Switching GLP-1 Medications Reduce Side Effects?

Sometimes.

Patients may tolerate semaglutide, tirzepatide or liraglutide differently.

However, switching within the incretin class does not guarantee that nausea, constipation or other gastrointestinal symptoms will disappear.

A medication switch should be based on:

• Current side effects
• Treatment response
• Medical history
• Indication
• Insurance coverage
• Patient preference

Can Compounded GLP-1 Medications Have Different Side Effects?

Yes.

Compounded products can introduce additional variables such as:

• Different concentrations
• Different delivery devices
• Dosing in milliliters or units rather than branded pen doses
• Different excipients
• Medication-preparation errors

FDA has warned about dosing errors involving compounded semaglutide, including cases requiring hospitalization.

Patients can review:

• Compounded semaglutide for weight loss
• Compounded tirzepatide for weight loss
• Compounded liraglutide for weight loss

Why the Exact Concentration Matters With Compounded Products

A branded pen is designed around a standardized concentration and device.

Compounded products may use different concentrations.

A patient who confuses:

• Milligrams
• Milliliters
• Syringe units

can accidentally administer much more medication than intended.

Unexpectedly severe nausea, vomiting or dehydration after a compounded injection warrants immediate review of the actual product, concentration and dose.

Should Side Effects Be Reported?

Persistent, severe or unusual symptoms should be reported to the prescribing clinician.

Clinicians and patients can also report suspected medication adverse events through FDA's MedWatch program.

Reporting helps regulators identify safety signals that may not be apparent during preapproval trials.

What Symptoms Require Prompt Medical Attention?

Seek prompt medical evaluation for:

• Severe persistent abdominal pain
• Pain radiating to the back
• Persistent vomiting
• Inability to maintain hydration
• Severe abdominal distention
• Inability to pass stool or gas
• Yellowing of the skin or eyes
• Fever with upper-abdominal pain
• Fainting
• Serious allergic-reaction symptoms
• Repeated significant hypoglycemia
• New major vision changes in a patient with diabetes

Which Symptoms Can Usually Be Discussed at Routine Follow-Up?

Milder symptoms that are often appropriate for routine or near-term discussion include:

• Mild intermittent nausea
• Mild constipation
• Occasional diarrhea
• Mild reflux
• Belching
• Minor injection-site irritation
• Hair shedding
• Mild fatigue

Any symptom that becomes severe, persistent or progressively worse should be escalated sooner.

How Can Patients Track Side Effects?

A simple symptom log can include:

• Medication and dose
• Date of injection or dose
• Meal timing
• Symptom onset
• Symptom severity
• Fluid intake
• Bowel movements
• Weight trend
• Any medication changes

This can help the clinician distinguish medication effects from unrelated symptoms.

Why Side-Effect Timing Matters

Symptoms that repeatedly appear after each dose or dose increase may be medication-related.

Symptoms that begin abruptly after months of stable treatment may require evaluation for another cause.

Not every stomach problem in a person taking a GLP-1 medication is caused by the GLP-1 medication.

Can Side Effects Improve Over Time?

Yes.

Major clinical trials and current product labels indicate that many gastrointestinal events are most common during dose escalation and often decrease over time.

In STEP 1, nausea and diarrhea with semaglutide were generally transient and mild to moderate.

In SURMOUNT-1, gastrointestinal adverse events with tirzepatide were also mostly mild to moderate and occurred primarily during escalation.

This does not mean every patient's symptoms will resolve without intervention.

Do Side Effects Predict Better Weight Loss?

No reliable rule says that more nausea means better weight loss.

Patients do not need to feel sick for the medication to work.

Severe side effects can actually interfere with:

• Hydration
• Nutrition
• Exercise
• Medication adherence

Tolerability is an important treatment outcome.

Should Patients “Push Through” Side Effects?

Mild transient symptoms can often be managed while treatment continues.

Severe or persistent symptoms should not be ignored in an effort to reach a higher dose.

The goal is effective, sustainable treatment rather than maximum medication exposure.

Can Weight Loss Continue on a Lower Maintenance Dose?

Depending on the medication, more than one approved maintenance dose may be available.

Treatment should be individualized according to:

• Indication
• Weight response
• Glucose response
• Side effects
• Medical risk

The prescriber should determine whether a lower approved maintenance dose is appropriate.

Frequently Asked Questions About GLP-1 Side Effects

What are the most common side effects of GLP-1 medications?

Nausea, diarrhea, vomiting and constipation are the most common class-wide effects. Abdominal discomfort, indigestion, reflux, belching, bloating, fatigue, dizziness, headache, injection-site reactions and hair loss can also occur depending on the medication.

Why do GLP-1 medications cause nausea?

They affect appetite signaling and slow gastric emptying, which can increase fullness and nausea, especially during dose escalation.

How long does GLP-1 nausea last?

Many patients improve as the body adapts, particularly after dose escalation stabilizes. Persistent or severe nausea should be discussed with the prescriber.

Is nausea worse after increasing the dose?

Often. Current product labels note that gastrointestinal symptoms commonly cluster around dose escalation.

What helps nausea on Wegovy or Zepbound?

Smaller meals, slower eating, avoiding very large high-fat meals and maintaining hydration can help some patients.

What if I vomit after taking a GLP-1?

One isolated episode may be manageable, but repeated vomiting or inability to maintain hydration requires medical review.

Can GLP-1 medications cause diarrhea?

Yes. Diarrhea is common with semaglutide, tirzepatide and liraglutide.

Can GLP-1 medications cause constipation?

Yes. Constipation is common, particularly during substantial appetite reduction.

How do I prevent constipation on a GLP-1?

Consistent hydration, gradual fiber intake and physical activity can help. Severe constipation requires medical evaluation.

Can GLP-1 medications cause a bowel obstruction?

Postmarketing reports with semaglutide and tirzepatide include ileus and intestinal obstruction. These events are uncommon and their frequency is not established, but severe distention, vomiting or inability to pass stool or gas requires urgent evaluation.

Can Ozempic cause ileus?

Current Ozempic postmarketing labeling includes ileus, intestinal obstruction and severe constipation including fecal impaction.

Can Wegovy cause intestinal obstruction?

Current Wegovy postmarketing labeling includes ileus, intestinal obstruction and severe constipation including fecal impaction.

Can Zepbound cause intestinal obstruction?

Current Zepbound postmarketing labeling includes ileus, intestinal obstruction and severe constipation including fecal impaction.

Can GLP-1 medications cause gastroparesis?

They delay gastric emptying and can cause symptoms that overlap with gastroparesis. Severe persistent symptoms may require evaluation, and current labels generally do not recommend use in severe gastroparesis.

Can GLP-1 medications cause pancreatitis?

Acute pancreatitis has occurred with these medications. Severe persistent abdominal pain, especially pain radiating to the back, requires prompt medical evaluation.

Can GLP-1 medications cause gallstones?

Gallstones and gallbladder inflammation can occur. Rapid weight loss itself can also increase gallstone risk.

Can GLP-1 medications hurt the kidneys?

Severe vomiting or diarrhea can cause dehydration and acute kidney injury. Patients with persistent fluid loss should contact their clinician.

Can GLP-1 medications cause low blood sugar?

They can, especially when combined with insulin or sulfonylurea medications.

Can GLP-1 medications cause dizziness?

Yes. Possible causes include dehydration, low blood pressure, reduced calorie intake and hypoglycemia.

Can GLP-1 medications cause fatigue?

Yes. Fatigue can be related to medication, reduced calorie intake, dehydration, rapid weight loss or another medical issue.

Can GLP-1 medications cause headaches?

Headache is recognized with several products and may also be influenced by dehydration, food intake or glucose changes.

Can GLP-1 medications cause reflux?

Yes. Reflux and heartburn are recognized with semaglutide, tirzepatide and liraglutide products.

Can GLP-1 medications cause burping?

Yes. Belching is a recognized adverse effect and may be related to slower gastric emptying.

Can GLP-1 medications cause bloating?

Yes. Mild bloating can occur, but severe progressive distention with vomiting or bowel-obstruction symptoms requires medical evaluation.

Can Wegovy cause hair loss?

Yes. Hair loss is listed in current Wegovy labeling.

Can Zepbound cause hair loss?

Yes. Hair loss is listed in current Zepbound labeling and has been associated with weight reduction.

Is GLP-1 hair loss permanent?

Not necessarily. Rapid weight loss can cause temporary diffuse hair shedding. Persistent loss should be evaluated for nutritional, thyroid and other causes.

What is Wegovy dysesthesia?

Dysesthesia is altered or uncomfortable skin sensation such as tingling, burning or increased sensitivity.

How common is dysesthesia with Wegovy HD?

Current labeling reports dysesthesia in approximately 22% with Wegovy 7.2 mg compared with 6% at 2.4 mg and 0.3% with placebo.

Can Ozempic cause tingling or skin sensitivity?

Dysesthesia is included in current Ozempic postmarketing labeling.

Do GLP-1 medications cause muscle loss?

Substantial weight reduction can include some lean-tissue loss. Protein intake, resistance training and body-composition monitoring can help support muscle preservation.

Do GLP-1 medications cause dehydration?

They can indirectly contribute when nausea, vomiting, diarrhea or very low fluid intake leads to volume loss.

How much water should I drink on a GLP-1?

There is no universal target. Fluid needs depend on body size, activity, climate, kidney function and heart health.

Should I take electrolytes?

Not every patient needs electrolyte supplements. They may be useful during significant fluid loss, but kidney and cardiovascular conditions can affect what is safe.

Can GLP-1 medications cause a fast heart rate?

Some products can modestly increase resting heart rate. Persistent palpitations or racing heartbeat at rest should be reported.

Can GLP-1 medications cause low blood pressure?

Weight loss and reduced intake can lower blood pressure. Tirzepatide labeling also recognizes hypotension in a small percentage of patients.

Can GLP-1 medications worsen diabetic retinopathy?

Rapid glucose improvement can temporarily worsen existing diabetic retinopathy in some patients. New vision changes should be reported.

Do GLP-1 medications increase suicide risk?

FDA concluded in January 2026 that its review did not identify an increased risk of suicidal ideation or behavior and requested removal of the prior warning from Wegovy, Zepbound and Saxenda labeling.

Can I take a GLP-1 before surgery?

Medication and fasting plans should be determined by the anesthesia or procedural team. Always tell them that you use a GLP-1-based medication.

Why do GLP-1 medications matter before anesthesia?

They delay gastric emptying, and pulmonary aspiration has been reported during general anesthesia or deep sedation.

Do GLP-1 medications have a thyroid cancer warning?

Semaglutide, liraglutide and tirzepatide products carry boxed warnings concerning thyroid C-cell tumors observed in rodents. Human relevance remains uncertain.

Who should not use these medications because of thyroid history?

They are generally contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Can GLP-1 medications be used during pregnancy?

Weight-loss treatment should be reassessed during pregnancy. Product-specific pregnancy and preconception recommendations should be reviewed with the prescriber.

Does tirzepatide affect birth-control pills?

Yes. Oral hormonal contraceptive exposure can be reduced. Current tirzepatide labeling recommends additional or non-oral contraception for four weeks after starting and after each dose increase.

Can side effects improve if the dose is lowered?

They can, depending on the medication and the clinical situation. Dose changes should be directed by the prescriber.

Can I stay at a lower dose longer?

Some approved regimens allow delayed escalation when side effects are significant. The prescribing clinician should decide whether that is appropriate.

Should I increase my dose if weight loss slows?

Not automatically. Weight-loss plateaus are common, and dose changes should account for tolerability, indication and current response.

Which GLP-1 has the fewest side effects?

There is no single answer. Trial populations differ, and individual tolerability varies substantially.

Is Zepbound easier to tolerate than Wegovy?

There is no universal rule. Direct comparative studies evaluate efficacy and safety, but individual patients can tolerate one drug much better than another.

Can compounded GLP-1 medications cause more side effects?

They can introduce additional risks involving concentration, dosing errors and formulation differences. Compounded drugs are not FDA-approved generics.

What should I do if side effects suddenly become much worse after a compounded injection?

Contact the prescriber and verify the exact ingredient, concentration and dose administered. Severe symptoms require prompt medical evaluation.

Can GLP-1 coaching help side effects?

Coaching can help with meal size, hydration, fiber, protein intake and symptom tracking. It does not replace medical evaluation for severe symptoms.

When should I call my doctor about GLP-1 side effects?

Call for persistent or worsening symptoms, repeated vomiting, inability to hydrate, severe abdominal pain, significant dizziness, severe constipation, gallbladder symptoms, low blood sugar or new vision changes.

When should I seek urgent care?

Urgent evaluation is appropriate for severe persistent abdominal pain, serious allergic-reaction symptoms, fainting, severe dehydration, persistent vomiting, or signs of bowel obstruction.

Do I have to feel sick for the medication to work?

No. Greater nausea does not reliably mean greater weight loss.

Can side effects be managed without stopping treatment?

Often, yes. Mild symptoms may improve with time, slower escalation, meal changes and hydration. Severe or persistent symptoms may require dose adjustment or a medication change.

Get Help Managing GLP-1 Medication Side Effects in Frankfort, IN

GLP-1 and GLP-1-based medications can be highly effective, but tolerability matters.

The most common symptoms are usually gastrointestinal and often become easier to manage after dose escalation stabilizes.

Patients should not assume that every symptom is harmless.

Severe abdominal pain, persistent vomiting, inability to hydrate, bowel-obstruction symptoms, gallbladder symptoms, serious allergic reactions or recurrent hypoglycemia require medical attention.

A coordinated plan can combine medication management with nutrition, hydration, body-composition monitoring and behavioral support.

Call (765) 259-0545 or contact Charles Turner MD online to request a consultation.

Medical References

• Once-Weekly Semaglutide Produces Substantial Weight Reduction With Generally Transient Mild-to-Moderate Gastrointestinal Effects: STEP 1
• Tirzepatide Produces Substantial Weight Reduction With Gastrointestinal Events Occurring Mainly During Dose Escalation: SURMOUNT-1
• Liraglutide 3.0 mg Produces Clinically Meaningful Weight Reduction in Adults With Overweight or Obesity: SCALE Obesity and Prediabetes
• Semaglutide Produces Greater Weight Reduction Than Liraglutide With Both Treatments Demonstrating Established Clinical Safety Profiles: STEP 8
• Tirzepatide Produces Greater Average Weight Reduction Than Semaglutide in Adults With Obesity: SURMOUNT-5
• Semaglutide 7.2 mg Produces Greater Weight Reduction Than 2.4 mg in Adults With Obesity: STEP UP
• Joint Nutrition and Lifestyle Advisory for Supporting Patients Receiving GLP-1 Therapy for Obesity